OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Brody on the Potential Role for Bispecific Antibodies in MCL

November 18th 2020

Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.

Dr. Winter on the Utility of PI3K Inhibitors in CLL

November 18th 2020

Allison Winter, MD, discusses the utility of PI3K inhibitors in chronic lymphocytic leukemia.

Dr. Randall on Unmet Needs in Platinum-Resistant Ovarian Cancer

November 17th 2020

Leslie M. Randall, MD, MAS, discusses the unmet needs in platinum-resistant ovarian cancer.

Dr. Subramanian on the Potential Utility of Dostarlimab in Previously Treated NSCLC

November 17th 2020

Janakiraman Subramanian, MD, discusses the potential utility of dostarlimab in previously treated patients with non–small cell lung cancer.

Dr. Ramalingam on Limitations With Immunotherapy in NSCLC

November 17th 2020

Suresh S. Ramalingam, MD, FASCO, discusses limitations with immunotherapy in non–small cell lung cancer.

Dr. Awan on the Importance of Risk Stratification in CLL

November 17th 2020

Farrukh Awan, MD, discusses the importance of risk stratification in chronic lymphocytic leukemia.

Dr. El Chaer on the Limitations of JAK Inhibitors in Myelofibrosis

November 17th 2020

Firas El Chaer, MD, discusses the limitations of JAK inhibitors in myelofibrosis.

Dr. Cavnar on the Roles of Chemotherapy and Surgery in Metastatic CRC

November 17th 2020

Michael J. Cavnar, MD, discusses the roles of chemotherapy and surgery in metastatic colorectal cancer.

Cancer Experts Spotlight the Significance of the Institutional Perspectives in Cancer Webinars

November 17th 2020

The Institutional Perspectives in Cancer webinars assemble academic and community-based physicians and healthcare professionals across key disciplines, ranging from medical to surgical oncology.

Dr. Ayers on Unmet Needs in CLL

November 16th 2020

Emily C. Ayers, MD, discusses unmet needs in chronic lymphocytic leukemia.

Dr. Brar on the Rise of New Treatment Approaches in HCC

November 16th 2020

Gagandeep Brar, MD, discusses the rise of new treatment approaches in hepatocellular carcinoma.

Dr. Ruan on the Evolving Armamentarium in MCL

November 16th 2020

Jia Ruan, MD, PhD, discusses the evolving armamentarium in mantle cell lymphoma.

Dr. Randall on the Evolution of Orthopedic Surgery in Sarcoma

November 16th 2020

R. Lor Randall, MD, FACS, discusses the evolution of orthopedic surgery in sarcoma.

Dr. Costello on Tailoring Induction Therapy for Standard- and High-Risk Multiple Myeloma

November 16th 2020

Caitlin Costello, MD, discusses tailoring induction therapy for patients with standard-risk and high-risk multiple myeloma.

Dr. Eng on the Role of Adjuvant Chemotherapy in CRC

November 16th 2020

Cathy Eng, MD, FACP, FASCO, discusses the role of adjuvant chemotherapy in colorectal cancer.

Dr. Jagadeesh on Unmet Needs in Aggressive and Rare Lymphoma Subtypes

November 14th 2020

Deepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.

Dr. Patel on Limitations With Chemotherapy in Pancreatic Cancer

November 14th 2020

Reema A. Patel, MD, discusses limitations with chemotherapy in pancreatic cancer.

Dr. Haas on the Role of PSMA in Prostate Cancer

November 14th 2020

Naomi B. Haas, MD, discusses the role of prostate-specific membrane antigen in prostate cancer.

Dr. Lee on the Rationale for Evaluating Telaglenastat in RCC

November 13th 2020

Chung-Han Lee, MD, PhD, discusses the rationale for evaluating telaglenastat in renal cell carcinoma.

Dr. Zalcberg on the Approval of Avapritinib in GIST

November 12th 2020

John Zalcberg, PhD, OAM, discusses the approval of avapritinib in gastrointestinal stromal tumor.